Conferences
Conferences
Advertisement
Cecilia BrownBreast Cancer | January 16, 2025
Researchers explored the real-world outcomes and management strategies in patients receiving the antibody-drug conjugate.
Read More
Laura LitwinGVHD | January 10, 2025
Learn how oral dysbiosis correlates with exacerbated cGVHD in patients after receiving hematopoietic cell transplantation.
Prithviraj Bose, MDMPN | January 7, 2025
Prithviraj Bose, MD, unpacks key highlights in MPN treatment and research at ASH 2024.
Amy Pierre, RN, BSN, ANP-BCMultiple Myeloma | December 31, 2024
Amy Pierre, RN, BSN, ANP-BC, explains why it's important for advanced practice nurses to be invovled in research.
Lisa Hwa, APRN, CNP, DNP, MSProfessional Development | December 27, 2024
Lisa Hwa, APRN, CNP, DNP, MS, is a member of the ASH Medical Educators Institute and has presented multiple ASH abstracts.
Katie KoskoGVHD | December 26, 2024
Research presented at ASH 2024 highlighted the importance of absolute monocyte counts after transplant.
Katie KoskoGVHD | December 24, 2024
Research presented at ASH 2024 showed that adding budesonide didn’t compromise immunologic recovery and transplant ...
Katie KoskoGVHD | December 23, 2024
A study presented at the 2024 ASH Annual Meeting suggests that a certain test may predict GI issues caused by GVHD.
Cecilia BrownConferences | December 20, 2024
Pierluigi Porcu, MD, discusses the phase II Tellomak trial and how nurses can help patients manage this rare disease.
Amy Pierre, RN, BSN, ANP-BCConferences | December 20, 2024
Amy Pierre, RN, BSN, ANP-BC, reflects on highlights from ASH 2024 and why it's critical for advanced practitioners to attend.
Kirk R. Schultz, MD, FCAHSConferences | December 20, 2024
An expert in pediatric GVHD shares his hopes and projections for the future of GVHD treatment and research.
Samantha Shenoy, NPConferences | December 20, 2024
Samantha Shenoy, NP, shares why it's important for nurses and APPs to consider attending the annual meeting.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPOConferences | December 19, 2024
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, discusses the significance of ASH 2024.
Ellinor Goergen, MDConferences | December 19, 2024
The CLL12 trial included patients with treatment-naive, asymptomatic, early-stage chronic lymphocytic leukemia.
Cecilia BrownConferences | December 18, 2024
Researchers evaluated treatment patterns, blood count control, and use of phlebotomy in patients with polycythemia vera.
Lisa Hwa, APRN, CNP, DNP, MSConferences | December 18, 2024
Lisa Hwa, APRN, CNP, DNP, MS, discusses her work with the ASH Medical Educators Institute and her conference experience.
Amy Pierre, RN, BSN, ANP-BCConferences | December 18, 2024
Amy Pierre, RN, BSN, ANP-BC, shares insights and key action items from her ASH 2024 presentation on the topic.
Richard Newcomb, MDConferences | December 17, 2024
Richard Newcomb, MD, shares insights from his ASH 2024 presentation and explains why nurses play a major role in outcomes.
Irwin Walker, MBBSConferences | December 17, 2024
Irwin Walker, MBBS, shares how he's seen the meeting evolve since his first time attending in 1971.
Cecilia BrownConferences | December 18, 2024
An ASH 2024 presentation of data from the Myelofibrosis and Essential Thrombocythemia Observational Study provided insights.
Advertisement
Advertisement
Advertisement